Transaction DateRecipientSharesTypePriceValue
8th September 2020Anthony Waclawski35,000Grant/award etc.$0.00
26th July 2020Chaim Lebovits31,185Grant/award etc.$0.00
16th July 2020David Setboun5,000Open or private purchase$12.95$64,740.00
16th July 2020International Holdings Ltd. Acc7,823Open or private sale$13.47$105,350.78
15th July 2020International Holdings Ltd. Acc18,430Open or private sale$13.12$241,714.98
15th July 2020Sankesh Abbhi46,779Open or private purchase$12.99$607,659.21
13th July 2020International Holdings Ltd. Acc40,000Open or private sale$13.52$540,952.00
10th July 2020International Holdings Ltd. Acc2,000Open or private sale$13.35$26,700.00
9th July 2020International Holdings Ltd. Acc3,500Open or private sale$13.13$45,938.55
2nd July 2020Anthony J. Polverino488Grant/award etc.$30.66$14,962.08
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Brainstorm Cell Therapeutics, Inc. was founded on September 22, 2000 and is headquartered in New York, NJ. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells.


Ticker: BCLI
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1137883
Employees: 32
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $12 M (2167%)
Assets, Current: $17 M (394%)
Property, Plant and Equipment, Net: $918 Th (-4%)
Other Assets, Noncurrent: $3 M (-18%)
Assets: $19 M (194%)
Accounts Payable, Current: $5 M (-68%)
Accrued Liabilities, Current: $2 M (102%)
Liabilities, Current: $9 M (-49%)
Liabilities: $9 M (-49%)
Common Stock, Value, Issued: $12 Th (9%)
Common Stock, Shares, Issued: $30 M (28%)
Additional Paid in Capital, Common Stock: $143 M (35%)
Retained Earnings (Accumulated Deficit): $133 M (13%)
Stockholders' Equity (Parent): $10 M (0%)
Liabilities and Equity: $19 M (194%)
Research and Development: $6 M (-51%)
General and Administrative Expenses: $2 M (-58%)
Operating Income/Loss: $7 M (-52%)